Loading clinical trials...
Loading clinical trials...
A Phase I/IIa, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV Vaccine Candidate in Adult Participants 18 to 50 Years of Age in Phase I, and 60 Years and Older in Phase IIa
Conditions
Interventions
RSV vaccine candiate formulation 1
RSV vaccine candidate formulation 2
+1 more
Locations
33
United States
Optimal Research Alabama Site Number : 8400032
Huntsville, Alabama, United States
Aventiv Research Mesa Site Number : 8400020
Mesa, Arizona, United States
CVS Health - Peoria Site Number : 8400042
Peoria, Arizona, United States
CVS Health - Phoenix Site Number : 8400041
Phoenix, Arizona, United States
Velocity Clinical Research - San Diego - ERN - PPDS Site Number : 8400010
La Mesa, California, United States
Peninsula Research Associates Site Number : 8400013
Rolling Hills Estates, California, United States
Start Date
November 17, 2022
Primary Completion Date
May 2, 2025
Completion Date
May 2, 2025
Last Updated
May 31, 2025
NCT07071558
NCT07164430
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions